MicroPact Participating in Landmark Opioid Alternative Project
The Chicago Sun Times this week cited MicroPact’s involvement in a new program in Illinois to combat the opioid crisis. The article, titled “Changes to medical pot program aim to eliminate months-long wait period,” discusses the Opioid Alternative Pilot Program (OAPP), which grants eligible patients access to medical cannabis as an alternative to opioids for chronic pain.
The OAPP, signed into law in August, will grant opioid patients a streamlined path to getting a medical cannabis license. It will also allow new applicants to purchase medical cannabis products while their applications are being processed. The Chicago Sun Times article details the struggles of current patients who have had to wait for months to get their medical cannabis licenses approved.
The article goes on to note that “Access for opioid patients and those seeking provisional coverage will open when MicroPact, a Virginia-based contractor, completes new software that will interact with the state’s existing cannabis monitoring systems.” The new system will be powered by the entellitrak® platform.
The OAPP is a creative and ambitious attempt to stem the opioid crisis. The long-term goal of the project is to reduce the number of opioid overdose deaths while providing pain relief to patients who need it.
Learn more about the role of case management solutions in the recent blog post, “How Can Technology Help Solve the Opioid Crisis?”
The proliferation of state laws governing medical marijuana use has created the need for systems to manage patient and other stakeholder registries. Regulators need dynamic software that is tailored to this unique regulatory challenge and diverse set of participants.
- MicroPact Powers Illinois Opioid Alternative Pilot Program February 12, 2019
- President’s Day and the Problem of Data Disconnect February 15, 2019
- Finding a Partner to Grow With February 14, 2019
- Modernize Your Apps, Keep Your Staff February 13, 2019
- State Healthcare IT Connect Summit March 18-20 Baltimore, Maryland